Cargando…
Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins
The safety and efficacy of several life-saving therapeutic proteins are compromised due to their immunogenicity. Once a sustained immune response against a protein-based therapy is established, clinical options that are safe and cost-effective become limited. Prevention of immunogenicity of therapeu...
Autores principales: | Nguyen, Nhan H., Glassman, Fiona Y., Dingman, Robert K., Shenoy, Gautam N., Wohlfert, Elizabeth A., Kay, Jason G., Bankert, Richard B., Balu-Iyer, Sathy V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426360/ https://www.ncbi.nlm.nih.gov/pubmed/34497305 http://dx.doi.org/10.1038/s41598-021-97333-0 |
Ejemplares similares
-
Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins
por: Jarvi, Nicole L., et al.
Publicado: (2021) -
Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development
por: Sauna, Zuben E., et al.
Publicado: (2023) -
Preclinical evaluation of cancer immune therapy using patient‐derived tumor antigen‐specific T cells in a novel xenograft platform
por: Shenoy, Gautam N, et al.
Publicado: (2021) -
Humanized Mouse Model of Ovarian Cancer Recapitulates Patient Solid Tumor Progression, Ascites Formation, and Metastasis
por: Bankert, Richard B., et al.
Publicado: (2011) -
Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments
por: Bhatta, Maulasri, et al.
Publicado: (2021)